Rhumbline Advisers Genmab A/S Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Genmab A/S stock. As of the latest transaction made, Rhumbline Advisers holds 18,694 shares of GMAB stock, worth $432,018. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,694
Previous 17,458
7.08%
Holding current value
$432,018
Previous $522,000
10.15%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding GMAB
# of Institutions
235Shares Held
48.7MCall Options Held
6.8KPut Options Held
27.6K-
Alliancebernstein L.P. New York, NY15.2MShares$352 Million0.14% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$117 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA4.23MShares$97.7 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.77MShares$64 Million0.4% of portfolio
-
Wellington Management Group LLP Boston, MA2.31MShares$53.3 Million0.01% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $15.2B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...